Bicycle Therapeutics PLCNASDAQ:BCYC
- LAST PRICE21.6500
- TODAY'S CHANGE (%)-0.4500 (-2.0362%)
- Bid / Lots21.6000/ 1
- Ask / Lots21.7600/ 2
- Open / Previous Close22.1000 / 22.1000
- Day Range
- 52 Week Range
- Volume22,199
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCYC |
|---|---|---|
| 09:32 ET | 830 | 22.43 |
| 09:34 ET | 100 | 22.245 |
| 09:36 ET | 100 | 22.145 |
| 09:38 ET | 100 | 22.2 |
| 09:45 ET | 300 | 22.08 |
| 09:48 ET | 600 | 22.02 |
| 09:50 ET | 100 | 22.02 |
| 09:52 ET | 400 | 21.81 |
| 09:54 ET | 300 | 21.75 |
| 09:57 ET | 599 | 21.825 |
| 09:59 ET | 200 | 21.71 |
| 10:03 ET | 1100 | 21.715 |
| 10:06 ET | 800 | 21.6394 |
| 10:08 ET | 5490 | 21.57 |
| 10:10 ET | 2861 | 21.65 |
| 10:12 ET | 200 | 21.685 |
| 10:15 ET | 100 | 21.65 |
Jun 3, 2024
Bicycle Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Monday Jun 03, 2024 by Dow Jones
7:00AM ET on Monday Jun 03, 2024 by Dow Jones
May 23, 2024
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC(R) Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by Dow Jones
5:05PM ET on Thursday May 23, 2024 by Dow JonesDJ Bicycle Therapeutics Shares Rise 15% on $555M Expected from Private Placement Deal, from 8:54AM ET on Thursday May 23, 2024 by Dow Jones
8:54AM ET on Thursday May 23, 2024 by Dow JonesBicycle Therapeutics Announces $555 Million Private Placement Equity Financing, from 7:00AM ET on Thursday May 23, 2024 by Dow Jones
7:00AM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicycle Therapeutics PLC | 1.5B | -4.9x | --- |
NewAmsterdam Pharma Company NV | 1.6B | -6.6x | --- |
Belite Bio Inc | 1.5B | -42.0x | --- |
Neumora Therapeutics Inc | 1.5B | -6.1x | --- |
Soleno Therapeutics Inc | 1.5B | -15.5x | --- |
Kura Oncology Inc | 1.6B | -9.1x | --- |
Company Information
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Contact Information
- Headquarters
- Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
- Phone
- 122-326-1503
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Pierre Legault
- Chief Executive Officer, Executive Director
- Kevin Lee
- Chief Financial Officer, Principal Financial Officer
- Alethia Young
- Chief Operating Officer
- Alistair Milnes
- Chief Technology Officer
- Michael Skynner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $41.6M |
Shares Outstanding | 68.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-4.45 |
Book Value | $8.74 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | 36.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -432.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
